Tensions show no sign of easing ahead of President Xi Jinping’s upcoming meeting with Obama
Time has run out for Procter & Gamble's CEO as the company turns to a famed management star
Surprise, surprise: Target, Macy's, and 15 other retailers are suing Visa and MasterCard over card fees
The odd-job marketplace is getting traction with business customers
Net flow into debt hedge funds is the highest since 2007
Roel Vertegaal's PaperTab is like an iPad you can fold, spindle, or mutilate
Networks are staggering première dates to capture viewers and ad dollars
Jim Dean, the dean of UNC's Kenan-Flagler School, calls it quits for a more lofty title: provost
Rob Rhinehart is living on a substance he engineered to replace food, and he just raised more than $200,000 through crowdfunding to manufacture it
Founders: Dr. Daniel J. Abrams; Tom Anchordoquy, PhD; and Karen Stevens, PhD
VC Investment over the last four quarters: $21.5 million
Founded in 2005, this seven-person biopharmaceutical company develops drugs for the treatment of severe central nervous system diseases. In addition to VC funding, Sierra received about $230,000 in grants from the State of Colorado, the University of Colorado, and the Coleman Institute. As for the recession, its founders say the company will be keeping close tabs on the funding and partnership environment over the next two to three years, despite already being funded for drug development work for the next three years.
Key to startup success: "Be persistent in the development of your data and business model to enable you to create a financial model that has a high likelihood of helping patients and therefore is fundable by the investor community."